HBK Sorce Advisory’s Capricor Therapeutics CAPR Stock Holding History

HBK Sorce Advisory’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$877K	Buy	223,076 +18,239	+9%	+$553K	0.02%	282
2026 Q1	$6.22M	Buy	204,837 +1,132	+0.6%	+$30.2K	0.12%	61
2025 Q4	$5.04M	Buy	203,705 +33,128	+19%	+$433K	0.12%	77
2025 Q3	$1.14M	Buy	170,577 +42,951	+34%	+$316K	0.03%	211
2025 Q2	$1.27M	Buy	127,626 +77,782	+156%	+$822K	0.03%	189
2025 Q1	$473K	Buy	+49,844	New	+$692K	0.01%	352

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HBK Sorce Advisory's CAPR Position: Q2 2026 in Review

HBK Sorce Advisory increased its Capricor Therapeutics (CAPR) stake by 8.9% in Q2 2026, buying an estimated $553K and bringing the position to 223,076 shares worth $877K. The position accounts for 0.02% of the portfolio, ranked #282.

HBK Sorce Advisory first reported a position in CAPR in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.22M in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

HBK Sorce Advisory held 223,076 shares of Capricor Therapeutics worth $877K as of Q2 2026.
HBK Sorce Advisory bought 18,239 Capricor Therapeutics shares in Q2 2026, an estimated $553K.
Capricor Therapeutics made up 0.02% of HBK Sorce Advisory's portfolio in Q2 2026, its #282 holding.
HBK Sorce Advisory first reported a position in Capricor Therapeutics in Q1 2025 and has held it in 6 quarters since.
HBK Sorce Advisory's Capricor Therapeutics position peaked at $6.22M in Q1 2026.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.